1. Gui, Shikai, Chen, Peng, Liu, Yu, Yuan, Shengtao, Cheng, Zujue. 2021. TUBA1C expression promotes proliferation by regulating the cell cycle and indicates poor prognosis in glioma. In Biochemical and biophysical research communications, 577, 130-138. doi:10.1016/j.bbrc.2021.08.079. https://pubmed.ncbi.nlm.nih.gov/34517210/
2. Jiang, Yi, Zhu, Chao, Huang, Haoxuan, Fu, Bin, Xi, Xiaoqing. 2023. TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle. In BMC cancer, 23, 716. doi:10.1186/s12885-023-11209-2. https://pubmed.ncbi.nlm.nih.gov/37528357/
3. Zhao, Yi, Wang, Wenwen, Li, Jinming, Zhao, Jiuda, Shen, GuoShuang. 2023. Elevated expression of TUBA1C in breast cancer predicts poor prognosis. In PloS one, 18, e0263710. doi:10.1371/journal.pone.0263710. https://pubmed.ncbi.nlm.nih.gov/38032902/
4. Wang, Haodong, Cui, Huaiping, Yang, Xinjun, Peng, Lipan. 2023. TUBA1C: a new potential target of LncRNA EGFR-AS1 promotes gastric cancer progression. In BMC cancer, 23, 258. doi:10.1186/s12885-023-10707-7. https://pubmed.ncbi.nlm.nih.gov/36941595/
5. Li, Junyi, Chen, Meixue, Tong, Ming, Cao, Qingfei. 2024. TUBA1C orchestrates the immunosuppressive tumor microenvironment and resistance to immune checkpoint blockade in clear cell renal cell carcinoma. In Frontiers in immunology, 15, 1457691. doi:10.3389/fimmu.2024.1457691. https://pubmed.ncbi.nlm.nih.gov/39301023/
6. Zou, Yiming, Wang, Guoqing, Fan, Min. 2022. Comprehensive Multiomic Analysis Identified TUBA1C as a Potential Prognostic Biological Marker of Immune-Related Therapy in Pan-Cancer. In Computational and mathematical methods in medicine, 2022, 9493115. doi:10.1155/2022/9493115. https://pubmed.ncbi.nlm.nih.gov/36466547/
智鼠故事 
